FY2026 EPS Estimates for Adherex Technologies Cut by Wedbush

Adherex Technologies Inc. (NASDAQ:FENC) – Investment analysts at Wedbush cut their FY2026 EPS estimates for shares of Adherex Technologies in a report issued on Monday, October 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $0.44 per share for the year, down from their previous estimate of $0.55. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share.

A number of other research firms also recently commented on FENC. Wall Street Zen upgraded shares of Adherex Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Craig Hallum increased their price objective on shares of Adherex Technologies from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, August 15th. Zacks Research downgraded shares of Adherex Technologies from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Adherex Technologies in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Adherex Technologies presently has an average rating of “Moderate Buy” and an average target price of $13.33.

Adherex Technologies Trading Down 2.0%

FENC opened at $8.27 on Tuesday. The stock has a market capitalization of $230.82 million, a P/E ratio of -19.69 and a beta of 0.64. Adherex Technologies has a 12 month low of $3.96 and a 12 month high of $9.92. The firm’s fifty day simple moving average is $8.82 and its 200 day simple moving average is $7.81.

Adherex Technologies (NASDAQ:FENC) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The company had revenue of $9.76 million for the quarter, compared to analyst estimates of $9.52 million.

Institutional Trading of Adherex Technologies

Several hedge funds and other institutional investors have recently modified their holdings of FENC. AQR Capital Management LLC bought a new position in Adherex Technologies in the 1st quarter valued at about $66,000. Jane Street Group LLC bought a new position in Adherex Technologies in the 1st quarter valued at about $90,000. Nuveen LLC bought a new position in Adherex Technologies in the 1st quarter valued at about $158,000. Finally, AIGH Capital Management LLC bought a new position in Adherex Technologies in the 1st quarter valued at about $2,199,000. Institutional investors own 55.51% of the company’s stock.

Insider Transactions at Adherex Technologies

In other news, major shareholder Southpoint Capital Advisors Lp sold 20,609 shares of the company’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $9.35, for a total value of $192,694.15. Following the sale, the insider directly owned 4,010,100 shares of the company’s stock, valued at approximately $37,494,435. This represents a 0.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $9.78, for a total transaction of $97,800.00. Following the completion of the sale, the director directly owned 82,501 shares in the company, valued at approximately $806,859.78. The trade was a 10.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 88,889 shares of company stock worth $831,426. 10.98% of the stock is owned by insiders.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.